CO6700846A2 - Sales de oxalato cristalinas de un compuesto diamida - Google Patents

Sales de oxalato cristalinas de un compuesto diamida

Info

Publication number
CO6700846A2
CO6700846A2 CO13061812A CO13061812A CO6700846A2 CO 6700846 A2 CO6700846 A2 CO 6700846A2 CO 13061812 A CO13061812 A CO 13061812A CO 13061812 A CO13061812 A CO 13061812A CO 6700846 A2 CO6700846 A2 CO 6700846A2
Authority
CO
Colombia
Prior art keywords
crystalline oxalate
oxalate salts
diamide compound
crystalline
salt
Prior art date
Application number
CO13061812A
Other languages
English (en)
Inventor
Miroslav Rapta
Venkat Thalladi
Robert Chao
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6700846A2 publication Critical patent/CO6700846A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a sales de oxalato cristalinas del l-(2-{[4-(4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2- dihidroquinolin-5-il) etilamino] - metil} fenilcarbamoil)butil]metilcarbamoil}etil)piperidin-4-il éster del ácido bifenil-2-ilcarbámico. Esta invención también se refiere a composiciones que contienen dicha sal de oxalatocristalina; métodos de uso de dicha sal de oxalato cristalina para, por ejemplo, tratar un trastorno pulmonar; y procesos para preparar dicha sal de oxalato cristalina.
CO13061812A 2010-09-30 2013-04-02 Sales de oxalato cristalinas de un compuesto diamida CO6700846A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38814810P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
CO6700846A2 true CO6700846A2 (es) 2013-06-28

Family

ID=44903347

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13061812A CO6700846A2 (es) 2010-09-30 2013-04-02 Sales de oxalato cristalinas de un compuesto diamida

Country Status (18)

Country Link
US (1) US8697724B2 (es)
EP (1) EP2621917A1 (es)
JP (2) JP2013538857A (es)
KR (1) KR20130139919A (es)
CN (1) CN103140485B (es)
AR (1) AR083115A1 (es)
AU (1) AU2011308770B2 (es)
BR (1) BR112013007062A2 (es)
CA (1) CA2810896A1 (es)
CL (1) CL2013000870A1 (es)
CO (1) CO6700846A2 (es)
EA (1) EA022018B1 (es)
IL (1) IL224985A (es)
MX (1) MX2013003558A (es)
NZ (1) NZ608721A (es)
SG (1) SG188390A1 (es)
TW (1) TW201217338A (es)
WO (1) WO2012044825A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN105142673B8 (zh) 2012-12-18 2018-02-16 阿尔米雷尔有限公司 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
OA12394A (en) 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
US7569586B2 (en) * 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
CA2758505C (en) 2009-04-23 2017-03-07 Theravance, Inc. Diamide compounds having muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activity

Also Published As

Publication number Publication date
AU2011308770B2 (en) 2015-03-05
CN103140485B (zh) 2014-10-22
JP2013538857A (ja) 2013-10-17
US8697724B2 (en) 2014-04-15
IL224985A (en) 2015-08-31
EA022018B1 (ru) 2015-10-30
TW201217338A (en) 2012-05-01
AU2011308770A1 (en) 2013-03-28
CL2013000870A1 (es) 2013-07-12
SG188390A1 (en) 2013-04-30
NZ608721A (en) 2015-03-27
EP2621917A1 (en) 2013-08-07
KR20130139919A (ko) 2013-12-23
AR083115A1 (es) 2013-01-30
JP2015155470A (ja) 2015-08-27
CN103140485A (zh) 2013-06-05
MX2013003558A (es) 2013-05-01
CA2810896A1 (en) 2012-04-05
WO2012044825A1 (en) 2012-04-05
BR112013007062A2 (pt) 2016-06-14
US20120083478A1 (en) 2012-04-05
EA201390481A1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
CO6700846A2 (es) Sales de oxalato cristalinas de un compuesto diamida
AR060648A1 (es) Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina
UY32062A (es) Inhibidores de beta-secretasa
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
AR106744A2 (es) Formas cristalinas de un compuesto de bifenilo
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
EA201491079A1 (ru) Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
CY1122670T1 (el) Παρασκευη παρασκευασματος και παρασκευασμα που περιλαμβανει αναστολεα μεκ
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
AR054425A1 (es) Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
MX2012000682A (es) Formas de bases libres cristalinas de un compuesto de bifenilo.
UY33380A (es) Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
BR102013003576B8 (pt) Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
CO6710915A2 (es) Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo
UA108378C2 (uk) Спосіб одержання плеуромутилінів
BR112015001890A2 (pt) inibidores de aril lactama quinase
BR112014026198A2 (pt) compostos pirazol como inibidores de sglt1
HK1168102A1 (en) Process for the preparation of a compound useful as an inhibitor of tafia
CL2011000093A1 (es) Compuestos derivados de un ester piperidinilico del acido bifenil-2-ilcarbamico; composicion farmaceutica; combinacion farmaceutica; y su uso para broncoconstriccion, enfermedades obstructivas o inflamatorias de las vias respiratorias.

Legal Events

Date Code Title Description
FG Application granted